MGMT, O-6-methylguanine-DNA methyltransferase, 4255

N. diseases: 444; N. variants: 24
Disease: Recurrent Childhood Glioblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 Biomarker disease BEFREE MMR-deficient rGBM showed significant telomere shortening and MGMT methylation and are characterized by highly heterogeneous MHC class I expression. 30514778 2019
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 AlteredExpression disease BEFREE We found that DYNC2H1 (DHC2) was expressed more in MGMT-deficient recurrent glioblastoma specimens and its expression strongly correlated to poor progression-free survival in MGMT promotor methylated glioblastoma patients. 31347685 2019
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 PosttranslationalModification disease BEFREE Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status. 30511935 2018
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 GeneticVariation disease BEFREE This was evaluated with particular reference to the impact of recurrent surgery for patients with unmethylated MGMT promoter rGB. 29425743 2018
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 GeneticVariation disease BEFREE The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O<sup>6</sup>-methylguanine-DNA-methyltransferase (MGMT) promoter methylation. 29892208 2018
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 PosttranslationalModification disease BEFREE MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. 28536992 2017
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 PosttranslationalModification disease BEFREE Temozolomide rechallenge is a treatment option for MGMT promoter-methylated recurrent glioblastoma. 25655102 2015
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 Biomarker disease BEFREE Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). 25163906 2014
CUI: C3897752
Disease: Recurrent Childhood Glioblastoma
Recurrent Childhood Glioblastoma 		0.090 PosttranslationalModification disease BEFREE MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. 23662801 2013